AUTOIMMUNE SYNDROMES IN MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CONGENIC STRAINS OF NONOBESE DIABETIC (NOD) MICE - THE NOD MHC IS DOMINANT FOR INSULITIS AND CYCLOPHOSPHAMIDE-INDUCED DIABETES

被引:156
作者
WICKER, LS
APPEL, MC
DOTTA, F
PRESSEY, A
MILLER, BJ
DELARATO, NH
FISCHER, PA
BOLTZ, RC
PETERSON, LB
机构
[1] CYTOTHERAPEUT,PROVIDENCE,RI 02906
[2] MERCK SHARP & DOHME LTD,DEPT IMMUNOL RES,RAHWAY,NJ 07065
[3] MERCK SHARP & DOHME LTD,DEPT CELLULAR & MOLEC PHARMACOL,RAHWAY,NJ 07065
[4] UNIV ROME LA SAPIENZA,DEPT ENDOCRINOL,I-00161 ROME,ITALY
关键词
D O I
10.1084/jem.176.1.67
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The development of autoimmune diabetes in the nonobese diabetic (NOD) mouse is controlled by multiple genes. At least one diabetogenic gene is linked to the major histocompatibility complex (MHC) of the NOD and is most likely represented by the two genes encoding the alpha and beta chains of the unique NOD class 11 molecule. Three other diabetogenic loci have recently been identified in the NOD mouse and are located on chromosomes 1, 3, and 11. In addition to the autoimmune diabetes which is caused by destruction of the insulin-producing beta cells in the pancreas, other manifestations of autoimmunity are seen in the NOD mouse. These include mononuclear cell inflammation of the submandibular and lacrimal glands, as well as the presence of circulating autoantibodies. To determine the effect of the non-MHC diabetogenic genes on the development of autoimmunity, we constructed the NOD.B10-H-2b (NOD.H-2b) strain, which possesses the non-MHC diabetogenic genes from the NOD mouse, but derives its MHC from the C57BL/10 (B10) strain. The NOD.H-2b strain does not develop insulitis, cyclophosphamide-induced diabetes, or spontaneous diabetes. It does, however, develop extensive lymphocytic infiltrates in the pancreas and the submandibular glands that are primarily composed of Thy 1.2+ T cells and B220+ B cells. In addition, autoantibodies are present in NOD.H-2b mice which recognize the "polar antigen" on the insulin-secreting rat tumor line RINm38. These observations demonstrate that the non-MHC genes in the NOD strain, in the absence of the NOD MHC, significantly contribute to the development of autoimmunity. The contribution of a single dose of the NOD MHC to autoimmunity was assessed with a (NOD x NOD.H-2b)F1 cross. Although only approximately 3% of F1 females developed spontaneous diabetes, approximately 50% of both female and male F1 mice developed insulitis, and 25% of females and 17% of males became diabetic after treatment with cyclophosphamide. These data demonstrate that the MHC-linked diabetogenic genes of the NOD mouse are dominant with decreasing levels of penetrance for the following phenotypes: insulitis > cyclophosphamide-induced diabetes > spontaneous diabetes.
引用
收藏
页码:67 / 77
页数:11
相关论文
共 24 条
  • [1] ASAMOTO H, 1984, Journal of the Japan Diabetes Society, V27, P775
  • [2] BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488
  • [3] TYPE-1 DIABETES IN MICE IS LINKED TO THE INTERLEUKIN-1 RECEPTOR AND LSH/ITY/BCG GENES ON CHROMOSOME-1
    CORNALL, RJ
    PRINS, JB
    TODD, JA
    PRESSEY, A
    DELARATO, NH
    WICKER, LS
    PETERSON, LB
    [J]. NATURE, 1991, 353 (6341) : 262 - 265
  • [4] DOTTA F, 1990, J AUTOIMMUN, V3, P59
  • [5] SIALADENITIS IN NONOBESE DIABETIC MICE - TRANSFER INTO SYNGENEIC HEALTHY NEONATES BY SPLENIC LYMPHOCYTES-T
    GOILLOT, E
    MUTIN, M
    TOURAINE, JL
    [J]. CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1991, 59 (03): : 462 - 473
  • [6] PROMOTION OF SPONTANEOUS DIABETES IN NON-OBESE DIABETES-PRONE MICE BY CYCLOPHOSPHAMIDE
    HARADA, M
    MAKINO, S
    [J]. DIABETOLOGIA, 1984, 27 (06) : 604 - 606
  • [7] THE NOD MOUSE - RECESSIVE DIABETOGENIC GENE IN THE MAJOR HISTOCOMPATIBILITY COMPLEX
    HATTORI, M
    BUSE, JB
    JACKSON, RA
    GLIMCHER, L
    DORF, ME
    MINAMI, M
    MAKINO, S
    MORIWAKI, K
    KUZUYA, H
    IMURA, H
    STRAUSS, WM
    SEIDMAN, JG
    EISENBARTH, GS
    [J]. SCIENCE, 1986, 231 (4739) : 733 - 735
  • [8] HAYASHI Y, 1989, CLIN EXP IMMUNOL, V78, P120
  • [9] JONSSON R, 1987, IMMUNOLOGY, V60, P611
  • [10] LIVINGSTONE A, 1991, J IMMUNOL, V146, P529